Indian Drug Makers Move To Novel Drug Delivery Systems
This article was originally published in PharmAsia News
India is expected to ride the drug industry trend toward new ways to deliver new drugs to patients, a growing segment of the pharmaceutical industry. Many Indian drug makers are working on novel drug discovery systems, already comprising nearly six percent of the Indian market. Revenues from NDDS products are expected to generate 29 percent annual growth in India, compared with 17 percent by the industry at large. Much of the new focus by drug makers results from a shrinking number of innovative drugs coming on the market at the same time blockbuster drugs lose their patent protections. (Click here for more
You may also be interested in...
Hyderabad, India-based Dr. Reddy's announced Feb. 8 an agreement with drug delivery firm SkyePharma to conduct a feasibility study of a Dr. Reddy's product utilizing two of the London-based firm's drug delivery systems. Dr. Reddy's will fund the study and pay SkyePharma an up-front fee. SkyePharma was unwilling to share further details on the agreement with PharmAsia News. Indian firms such as Dr. Reddy's are increasingly turning to novel drug delivery systems to strengthen their products' market position (PharmAsia News, Feb. 7, 2008)
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.